Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18034508 | 0.61 | LMNA (0.33) | LMNAHTTSMN1; SMN2POLBSTAT3 | |
| SCHEMBL18034515 | 0.61 | LMNA (0.84) | LMNAHTTSMN1; SMN2POLBNPC1 | |
| SCHEMBL18034496 | 0.59 | LMNA (0.69) | LMNAHTTSMN1; SMN2POLBNPC1 | |
| SCHEMBL18034516 | 0.57 | LMNA (1.00) | LMNAHTTSMN1; SMN2POLBNPC1 | |
| SCHEMBL29709886 | 0.57 | LMNA (1.00) | LMNAHTTSMN1; SMN2POLBNPC1 | |
| SCHEMBL7922761 | 0.56 | JUN (0.39) | JUNLMNAHTTSMN1; SMN2POLB | |
| SCHEMBL7497662 | 0.56 | JUN (0.39) | JUNLMNAHTTSMN1; SMN2POLB | |
| SCHEMBL24637625 | 0.46 | JUN (0.33) | JUNLMNASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL15998816 | 0.46 | — | — | |
| SCHEMBL24796620 | 0.46 | PTPN1 (0.32) | LMNAHTTSMN1; SMN2NPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-107089993-B | Hypolipidemic activity bamboo-cypress lactone compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-07-09 | — | — | CN | disclosed |
| CN-107405330-B | Bamboo Bai ester compound with hypolipidemic activity, and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | JUN 3792/4885LMNA 2407/4885HTT 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.